NCT06556368Phase 3Active not recruiting

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

Study sponsor: Kodiak Sciences Inc · KOD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-08Estimated

Enrollment · participants675Estimated

Source updated2026-04-29Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-10-27 · 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Best corrected visual acuity (~~PCVA~~

+ After

Measure: Best corrected visual acuity (BCVA)

Primary completion date changed

− Before

~~Apr 2026~~

+ After

Aug 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source